The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2025 | Improving lung cancer diagnosis and treatment with genomics: lessons from the BTOG 2025 congress
Adam Januszewski, PhD, St Bartholomew’s Hospital, London, UK, comments on the implementation of genomics in the UK, highlighting the complexity of the pathway from first contact with the patient to delivering results, and the need for a joined-up approach to improve pathway times. He notes that the outcomes of the circulating tumour DNA (ctDNA) pilot study have been promising, with a reduction in time to deliver genetic results, but emphasizes the need for continued recruitment of patients to demonstrate the impact. This interview took place at the BTOG 2025 congress in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
